Bumetanide Injection
Last Updated: January 23, 2023
Status: Current
Products Affected - Description
-
- Bumetanide injection, Athenex, 0.25 mg/mL, 10 mL vial, 10 count, NDC 70860-0406-10
- Bumetanide injection, Athenex, 0.25 mg/mL, 4 mL vial, 10 count, NDC 70860-0405-04
- Bumetanide injection, Hikma, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00641-6007-10
- Bumetanide injection, Hikma, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00641-6008-10
- Bumetanide injection, Pfizer, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00409-1412-10 - discontinued
- Bumetanide injection, Pfizer, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00409-1412-04 - discontinued
Reason for the Shortage
-
- Athenex launched bumetanide injection in February 2022.
- Hikma did not provide a reason for the shortage.
- Pfizer has discontinued bumetanide injection in August 2022.
Available Products
-
- There is insufficient supply for usual ordering
Estimated Resupply Dates
-
- Athenex has bumetanide 0.25 mg/mL 4 mL and vials on back order and the company estimates a release date of February 2023.
- Hikma has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on allocation.
Updated
Updated January 23, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 23, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.